Thomas Andrew Crockett, CEO at KalVista Pharmaceuticals, Inc. (KALV), sold 10,000 shares at $17.07 ($171K) on 2022-03-09, disclosed to the SEC on 2022-03-11.
Open-market sale of $171k KALV by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| Filing → |
| KALV | SELL | 2024-02-05 | $162K | — | Filing → |
| KALV | SELL | 2023-12-28 | $361K | — | Filing → |
| KALV | SELL | 2023-11-21 | $244K | — | Filing → |